FIRST LINE THERAPY OF ADVANCED STAGE FOLLICULAR LYMPHOMA IN PATIENTS NOT ELIGIBLE FOR STANDARD IMMUNOCHEMOTHERAPY Prospective randomized comparison of single agent GA101 versus GA101 plus Bendamustine followed by GA101 in medically non-fit patients

Trial Profile

FIRST LINE THERAPY OF ADVANCED STAGE FOLLICULAR LYMPHOMA IN PATIENTS NOT ELIGIBLE FOR STANDARD IMMUNOCHEMOTHERAPY Prospective randomized comparison of single agent GA101 versus GA101 plus Bendamustine followed by GA101 in medically non-fit patients

Recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Bendamustine (Primary) ; Obinutuzumab (Primary)
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Acronyms GABe2016
  • Most Recent Events

    • 14 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top